Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.66 million versus the consensus estimate of $4.75 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.